Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain and eye clues to emotion recognition in autism and psychosis

NCT ID NCT05501405

Knowledge-focused Sponsor: Hôpital le Vinatier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to understand why people with autism or schizophrenia sometimes struggle to recognize emotions on faces. Researchers used brain wave recordings (EEG) and eye-tracking to see how participants processed facial expressions. The study included people with autism, schizophrenia, or certain genetic conditions, but was ended early after enrolling only 14 participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

14 people

The number who actually took part.

Started

Mar 2022

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals with a genetic condition with psychiatric expression (22q11.2 microdeletion syndrome, Williams syndrome, Präder-Willi syndrome) * Individuals with schizophrenia according to DSM-5 criteria * Individuals with Autism Spectrum Disorder (ASD) according to DSM-5 criteria * Individuals between the ages of 10 and 50 * French native language * Psychotropic treatment unchanged during the month preceding inclusion * Stable symptomatology * Individuals having given their informed consent to participate in the study (consent of legal tutors for minors or under tutorship Exclusion Criteria: * Recent addiction, excluding tobacco addiction (according to DSM-5 criteria) * Neurological disorders of vascular, infectious or neurodegenerative origin for patients with schizophrenia or ASD * Uncorrected visual acuity disorder * Use of somatic medications that have a cerebral or psychological impact (e.g. corticosteroids) * Pregnant women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for 22q11.2 deletion syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

22q11.2 deletion syndrome autism autism spectrum disorder Prader-Willi syndrome psychotic disorder Psychotic Disorders schizophrenia Williams syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autism Psychotic disorders

Contacts and locations

Locations

  • centre de réhabilitation - Hôpital le Vinatier

    Lyon, Rhône, 69006, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.